Lab Dept: Chemistry

Test Name: NEWBORN METABOLIC SCREEN, MINNESOTA

General Information

Lab Order Codes: PKUN

Synonyms: Newborn Screen for Hyopothyroidism, Phenylketonuria (PKU), Galactosemia, Hemoglobinopathy, and Congential Adrenal Hyperplasia (CAH); Congenial Adrenal Hyperplasia; Galactosemia Screen; Hemoglobinopathy Screen; Hypoithyroidism Screen; Inborn Errors of Metabolism Screen; Newborn Metabolic Screening; Phenylketonuria Screen; PKU Screen; Amino Acidemia; Fatty Acid Oxidation; Organic Acidemias; Cystic Fibrosis; PKU/Thyroid Newborn Screen; Severe Combined Immune Deficiency (SCID); X-linked Adrenoleukodystrophy

CPT Codes: S3620 – Newborn metabolic screening panel, including test kit, postage and the laboratory tests specified by the state for inclusion in this panel

Test Includes: Amino Acidemia Screen including: Phenylketonuria, Maple Syrup Disease, Citrullemia, Arginosuccinic Aciduria, Homocystinuria, Arginemia, Tyrosinemia Type I; Congenial Adrenal Hyperplasia Screen; Hypothyroid Screen (TSH), Fatty Acid Oxidation Screen including: Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Medium Chain Acyl-CoA Dehydrogenase Deficiency, Short Chain Acyl-CoA Dehydrogenase Deficiency, Long Chain Hydrozy Acyl-CoA Dehydrogenase Deficiency, Carnitine/acylcarnitine traslocase Deficiency, Carnitine Palmitoyl Transerase II Deficiency, Hydroxy Acyl-CoA Dehydrogenase 3-Ketoacyl-CoA Thiolase/Enoyl-CoA Hydratase Deficiency; Galactosemia Screen, Hemoglobinopathy Screen, Organic Acidemia Screen including: Glutaric Acidemia Type I, Propionic Acidemia, Methylmalonic Acidemia, Isovaleric Acidemia, 3-Methylcrotonyl-CoA Carboxylase Deficiency, 3-Hydroxy-Methyl-Glutaryl-CoA Lyase Deficiency; Cystic Fibrosis; Biotinidase; Galactose; X-linked Adrenoleukodystrophy; Lysosomal Disease Profile (Mucopolysaccharidosis type I – MPS1 and Pompe Disease); Spinal Muscular Atrophy (SMN1 gene)

Logistics

Test Indications: State of Minnesota requires newborn screening for common metabolic disorders or disease states which can lead to clinical consequences such as mental retardation, hemolytic episodes, and death.

See Special Instructions for more information.

Lab Testing Sections: Chemistry - Sendouts

Referred to: Minnesota Department of Health
**Phone Numbers:**
- MIN Lab: 612-813-6280
- STP Lab: 651-220-6550

**Test Availability:**
Daily, 24 hours

**Turnaround Time:**
5 - 7 days, test set up Monday - Friday

**Special Instructions:**

**Infants >1800 grams at birth:**
Newborn screening should be collected between 24-48 hours after birth. Infants <24 hours old requiring any blood cell or blood product (ie, FFP, cryoprecipitate, platelets) transfusion should have a newborn screening card collected prior to transfusion. A second card should be collected at the normal time when the infant is >24 hours old. The second card should indicate that the sample is post-transfusion. Depending on the results, a third card may be required 2 months post transfusion.

Infants <24 hours old who are transfused, but NO card was collected prior to transfusion should have a card collected at the normal time when the infant is >24 hours old. That card should indicate post transfusion. A second collection may be required may be required 2 months post transfusion depending on the Newborn Screening Results.

**Infants <1800 grams at birth:**
Infants weighing less than 1800 grams should have three newborn screens collected. An initial screen should be collected between 24 and 48 hours of age and subsequent specimens should be collected at 14 and 30 days of age. If an infant requires a transfusion prior to 24 hours of age, a specimen should be collected pre-transfusion, but the second specimen will not be collected until 14 days of age. If an infant is discharged prior to this time when a subsequent screen would be done, the specimen should be collected at the time of discharge. In order to help keep track of specimens from infants weighing less than 1800 grams, special yellow NICU newborn screening cards have been printed. They can be ordered through the Financial Management area of the Minnesota Department of Health, just like traditional cards are ordered.

See Limitations for further explanation of the impacts of blood transfusion on Newborn Screening results.

---

**Specimen**

**Specimen Type:** Whole blood

**Container:** Minnesota Department of Health specimen collection card

**Draw Volume:** Approximately 0.5 mL blood

**Processed Volume:** 5 completely filled circles on specimen card
**Collection:**

Warm the heel. Sterilize skin and allow to thoroughly air dry. Puncture heel with sterile, disposable lancet, using a firm, quick stab making a 1mm incision, 2.5 mm long. For premies, it is safer to make the incision more shallow. Allow a large drop of blood to accumulate and wipe away with sterile gauze. Allow a second large drop of blood to accumulate. Apply the second drop to the reverse side of the filter paper until the circle is filled completely when viewed from the other side. Avoid repeated applications to filter paper to fill one circle. Allow circles to fill by natural flow. Do not touch filter paper to puncture site. Avoid squeezing tissue to obtain blood as this may dilute the specimen. Avoid touching blood collection area of filter paper prior to, during, and following sampling. Completely fill all circles on the filter paper collection form. Allow blood spots to air dry for a minimum of three (3) hours. **Do Not** expose to heat or moisture.

**Note:** For all patients a heel stick is the preferred standard method of collection yielding the highest quality results. Poor quality specimens place an unnecessary burden on the screening facility, cause unnecessary trauma to the infant and anxiety to the infant's parents, potentially delay the detection and treatment of the affected infant, and may contribute to a missed or late diagnosed case. **Premies and sick newborns:** If appropriate, a heel stick can also be used for this patient population. However, if indicated, blood can be drawn from an umbilical catheter line. Make sure to draw off 2-2.5 mL’s before collecting the newborn screening specimen. Collect the blood in a syringe and apply it to the circles immediately to avoid blood clots that would make the specimen unsatisfactory. Each circle holds 0.1 mL’s of blood.

The filter paper cannot have multiple applications of blood, each spot needs to be filled from a one time application.

See **Special Instructions** for information on timing of collections.

**Special Processing:**

**Do Not** dry specimen under a lamp.

Please complete all the information requested on the collection card: mother’s full name, baby’s name, baby’s date of birth, birth-weight, hospital of birth and time of specimen collection.

**Do Not** fold filter paper or form

**Patient Preparation:**

See **Collection**

**Sample Rejection:**

Multiple applications of blood to the filter paper; less than 5 circles filled on the collection filter paper; specimens collected from a syringe

**Interpretive**

**Reference Range:**

<table>
<thead>
<tr>
<th>Galactosemia (GALT &amp; TGAL)</th>
<th>Within Normal Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>GALT &gt;3.2 U/dL</td>
<td></td>
</tr>
<tr>
<td>TGAL &lt;12 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Status</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Hemoglobinopathies</td>
<td>Within Normal Limits (Within Normal Limits = FA)</td>
</tr>
<tr>
<td>Congenital Hypothyroidism (TSH)</td>
<td>Within Normal Limits (Age dependent)</td>
</tr>
<tr>
<td>Amino Acidemia Profile</td>
<td>Within Normal Limits</td>
</tr>
<tr>
<td>Cystic Fibrosis (IRT)</td>
<td>Within Normal Limits &lt;96th Percentile</td>
</tr>
<tr>
<td>Acylcarnitine Profile</td>
<td>Within Normal Limits</td>
</tr>
<tr>
<td>Biotinidase Deficiency (BTD)</td>
<td>Within Normal Limits (&gt;55 U/dL)</td>
</tr>
<tr>
<td>Congential Adrenal Hyperplasia (17-OHP)</td>
<td>Within Normal Limits (Weight Dependent)</td>
</tr>
<tr>
<td>SCID/Primary T-cell lymphopenia</td>
<td>Negative (TREC Present)</td>
</tr>
<tr>
<td>X-linked Adrenoleukocystrophy (C26:0-LPC)</td>
<td>Within Normal Limits (&gt;0.4 uM C26:0-LPC)</td>
</tr>
<tr>
<td>Lysosomal Disease Profile</td>
<td>Within Normal Limits (Enzyme Activity Present)</td>
</tr>
<tr>
<td>Spinal Muscular Atrophy (SMN1 gene)</td>
<td>Within Normal Limits (SMN1 Present)</td>
</tr>
</tbody>
</table>

**Critical Values:** Any positive or abnormal

**Limitations:**
If an infant requires any type of blood transfusion, collect the blood spots before blood products are administered, even if the infant is less than 24 hours of age. If the pre-transfusion specimen was collected prior to 24 hours of life, a subsequent specimen should be collected after 24 hours. In all instances where a specimen was collected prior to 24 hours of life from an infant weighing less than or equal to 1800 grams, the subsequent specimen can be collected at 14 days of age instead of at the usual 24-48 hours of life.

The first specimen will allow for accurate interpretation for biotinidase deficiency, cystic fibrosis, galactosemia, hemoglobinopathy, and severe combined immune deficiency results. Because these screening results are impacted by transfusions, collecting a blood specimen prior to transfusion is critical in determining whether an infant is at risk for these disorders. The second specimen will be used to screen for the remaining disorders, which are affected by the timing of collection.
If an infant is transfused and a prior specimen was not collected, a specimen should be collected between the optimal time of 24-48 hours of life or as soon as possible, and a second specimen should be collected at 90 days after the last transfusion. The 90-day specimen allows the Newborn Screening Program to accurately interpret those results that are impacted by transfusion.

**Methodology:**

- **Congenital Hypothyroidism:** TSH/17OHP: fluoroimmunoassay
- **Congenital Adrenal Hyperplasia:** Quantitative time-resolved fluoroimmunoassay
- **Cystic Fibrosis:** Immunoreactive Trypsinogen with PCR follow-up for positives
- **Galactosemia/Galactose-1-phosphate uridylytransferase:** Enzyme by semi-quantitative fluorometric assay; Total Galactose: Quantitative fluorometric assay
- **Hemoglobinopathies:** Isoelectric focusing
- **Biotinidase:** Biotinidase enzyme by qualitative colorimetric assay
- **Amino Acidemias:** Tandem Mass Spectrometry (MS/MS)
- **Organic Acidemias:** Tandem Mass Spectrometry (MS/MS)
- **SCID:** Tandem Mass Spectrometry (MS/MS)
- **X-linked Adrenoleukodystrophy:** Tandem Mass Spectrometry (MS/MS)
- **Lysosomal Disease Profile:** Tandem Mass Spectrometry (MS/MS)
- **Spinal Muscular Atrophy:** Realtime Quantitative PCR (qPCR)

**References:**

Minnesota Department of Health January 2018

**Updates:**

1/17/2006: Added information regarding patients under 1800 grams and collection procedure changes for them.
3/8/2006: Updated with additional information regarding addition of CF to the screen on 3/1/2006. Also the addition of 83516 as the CPT code for this test.
9/30/2008: Heel stick/line draw clarification confirmed by MN Dept of Health.
9/15/2014: Added Limitations explaining the impact of specimen collection timing and transfusions.
12/12/2016: Added info about SCID and X-ALD.
8/2/2017: Added info about Lysosomal Disease Profile, newly added testing.
01/22/2018: Added information about Spinal Muscular Atrophy, newly added testing.